Pfizer (PFE) Q4 2024 earnings summary

Executive summary

• Achieved strong execution in 2024, meeting or exceeding strategic and financial goals, including successful integration of Seagen, restructuring commercial operations, and new R&D leadership.

• Leveraged AI and data-driven strategies to enhance commercial effectiveness, resulting in top industry rankings and improved market share across key specialties.

• Advanced R&D pipeline with over a dozen approvals, multiple pivotal study starts, key phase III readouts, and reorganized R&D into four focused units for greater agility.

• Achieved $4B in net cost savings in 2024, with a target of $4.5B by end of 2025.

• 2025 priorities include improving R&D productivity, maintaining margin expansion, and disciplined capital allocation.

Financial highlights

• Full year 2024 revenues reached $63.6B, up 7% from 2023; operational revenue growth excluding COVID products was 12%.

• Adjusted diluted EPS for 2024 was $3.11, up 69% from 2023; reported diluted EPS was $1.41.

• Q4 2024 revenues were $17.8B, up 21% year-over-year; non-COVID product revenues grew 11%.

• Cost of sales as a percentage of revenue decreased to 28.1% in 2024 from 41.9% in 2023.

• $9.5B returned to shareholders and $7.8B in debt paid down in 2024.

Outlook and guidance

• 2025 revenue guidance: $61B–$64B; adjusted diluted EPS guidance: $2.80–$3.00.

• Adjusted SI&A expenses expected at $13.3B–$14.3B; adjusted R&D expenses at $10.7B–$11.7B; effective tax rate ~15%.

• No share repurchases anticipated in 2025; focus on deleveraging and balanced capital allocation.

• Expect $4.5B in net cost savings from ongoing realignment by end of 2025.

• IRA Medicare Part D redesign expected to reduce 2025 revenue by ~$1B, with higher gross-to-net impact early in the year.